Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)

Phase 3Recruiting

2 views this week 0 watching⚡ Active🏛️Featured in Big Pharma Pipeline

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Extensive-stage Small-cell Lung Cancer

Conditions

Extensive-stage Small-cell Lung Cancer

Trial Timeline

Feb 3, 2025 → Mar 1, 2029

NCT ID

NCT06712355

About Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)

Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated) is a phase 3 stage product being developed by Bristol Myers Squibb for Extensive-stage Small-cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06712355. Target conditions include Extensive-stage Small-cell Lung Cancer.

What happened to similar drugs?

0 of 6 similar drugs in Extensive-stage Small-cell Lung Cancer were approved

Approved (0) Terminated (1) Active (5)

🔄SHR-1316 + Carboplatin + Etoposide + PlaceboJiangsu Hengrui MedicinePhase 3

🔄Durvalumab + Cisplatin + Carboplatin + EtoposideAstraZenecaPhase 3

🔄Tarlatamab + DurvalumabAmgenPhase 3

🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3

❌ZL-2306(nirapairb) + PlaceboZai LabPhase 3

🔄Carboplatin + Palifosfamide-tris + Etoposide + CarboplatinAlaunos TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06712355	Phase 3	Recruiting	Feb 3, 2025	Mar 1, 2029	Extensive-stage Small-cell Lung Cancer

Competing Products

20 competing products in Extensive-stage Small-cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
Ifinatamab Deruxtecan (I-DXd)	Daiichi Sankyo	Phase 2	39
Valemetostat + Atezolizumab	Daiichi Sankyo	Phase 1	36
SHR-1316 + Carboplatin + Etoposide + Placebo	Jiangsu Hengrui Medicine	Phase 3	36
Neoantigen DNA vaccine + Durvalumab	AstraZeneca	Phase 2	39
Etoposide with Carboplatin or Cisplatin + Durvalumab	AstraZeneca	Phase 2	39
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + Carboplatin	AstraZeneca	Phase 1	33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparib	AstraZeneca	Phase 2	35
Durvalumab + Cisplatin + Carboplatin + Etoposide	AstraZeneca	Phase 3	40
Atezolizumab 1200 mg in 20 ML Injection + ADC Vaccine + Carboplatin	Roche	Phase 1/2	36
Tarlatamab + Durvalumab	Amgen	Phase 3	44
Carfilzomib + Carboplatin + Etoposide	Amgen	Phase 1/2	32
Tafolecimab + Sintilimab (approved) + Etoposide + Carboplatin / Cisplatin	Innovent Biologics	Phase 2	42
BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + Etoposide	Bristol Myers Squibb	Phase 3	47
BMS-986012 + Carboplatin + Etoposide + Nivolumab	Bristol Myers Squibb	Phase 2	39
Ivonescimab + Cadonilimab + AK117 + Etoposide + Carboplatin (AUC 5)	Akeso	Phase 2	42
Teniposide administration	China Resources Pharmaceutical Group	Phase 2	39
BNT327 Dose Level 1 (DL1) + BNT327 Dose Level 2 (DL2) + Etoposide + Carboplatin + Paclitaxel + Topotecan	BioNTech	Phase 2	36
Zepzelca	Jazz Pharmaceuticals	Pre-clinical	23
Lurbinectedin + Durvalumab	Jazz Pharmaceuticals	Phase 2	39
Surufatinib + Anti-PD-1/L1	HUTCHMED	Phase 2	29